The CC could of been very positive with a better strategy . “”” Both the FDA and MHRA are requesting to see interim data from cd12 before considering any type of approval “” Reasoning being that the pressing need is for patients on the cusp of severe sickness . The m/m group numbers were to small with many patients not symptomatic enough to give us confidence .

Can’t believe all the PHD’s who want free shares couldn’t figure this out.

We need a sharp PR firm no doubt about it .